Xenon Pharmaceuticals (XENE) Change in Acquisitions & Divestments (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 12 years of Change in Acquisitions & Divestments data on file, last reported at $98.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 40.59% year-over-year to $98.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $507.2 million (down 30.74% YoY) and the FY2025 annual result came in at $574.5 million, down 17.98% from the prior year.
• Change in Acquisitions & Divestments declined to $98.5 million in Q1 2026 per XENE's latest filing, from $123.9 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $235.7 million in Q2 2024 and bottomed at $20.3 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $136.9 million (2023), against an average of $136.6 million.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments plunged 55.87%; it then soared 674.7% in 2023.
• Tracing XENE's Change in Acquisitions & Divestments over 5 years: stood at $104.8 million in 2022, then soared by 30.66% to $136.9 million in 2023, then rose by 21.01% to $165.6 million in 2024, then dropped by 25.19% to $123.9 million in 2025, then decreased by 20.51% to $98.5 million in 2026.
• Per Business Quant, the three latest XENE Change in Acquisitions & Divestments figures stand at $98.5 million (Q1 2026), $123.9 million (Q4 2025), and $113.5 million (Q3 2025).

Peer Comparison